Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 1;19(2):pyv088. doi: 10.1093/ijnp/pyv088

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2015. Published by Oxford University Press on behalf of CINP.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Examination of the expression of molecules in the Notch signaling pathway in the forebrain of mice for all treatment groups (n=6 for each group). (A-B) RT-PCR showed no change of Notch2 (F _{3, 25}=0.323, P=.809), and Notch4 levels (F _{3, 18} = 0.708, P=.56) in each group. (C-E) RT-PCR results demonstrated that Notch1, Hes1, and Hes5 were upregulated by quetiapine and downregulated by cuprizone. Notch1 (C) (F _{3, 24} = 8.335, P<.01), Hes1 (D) (F _{3, 22} = 8.637, P<.01), and Hes5 (E) (F _{3, 24} = 4.478, P<.05) all increased in the cuprizone/quetiapine cotreatment group. (F-H) Western-blot analysis showed decreased expressions of Hes1 (F _3,22=7.498, P<.01), and Hes5 (F _{3, 22}=10.335, P<.01) in CPZ group and were upregulated after quetiapine co-administration. *P<.05, **P<.01.